Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Hemophilia (Dec 2017)

Posted by Matt Breese on Dec 20, 2017

Find me on:

According to our recent payer coverage analysis for hemophilia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for hemophilia treatments shows the complex dynamics of pharmacy and medical benefit coverage across payer-controlled formularies. We saw a slight reduction in restricted lives across pharmacy benefit commercial and medical benefit medicare channels.

mmit-reality-check-hemophilia-dec17.png

Data current as of Q4 2017 

Trends: Anticipated product approvals may develop improved product placement based on potential cost, adherence and efficacy advantages.

To read the full Reality Check on Hemophilia treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 

reality-check-thumbnail-v1-1.png

View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing